CL2022001173A1 - Forma cristalina de la base libre de un receptor del componente c5a del complemento - Google Patents

Forma cristalina de la base libre de un receptor del componente c5a del complemento

Info

Publication number
CL2022001173A1
CL2022001173A1 CL2022001173A CL2022001173A CL2022001173A1 CL 2022001173 A1 CL2022001173 A1 CL 2022001173A1 CL 2022001173 A CL2022001173 A CL 2022001173A CL 2022001173 A CL2022001173 A CL 2022001173A CL 2022001173 A1 CL2022001173 A1 CL 2022001173A1
Authority
CL
Chile
Prior art keywords
free base
crystalline form
receptor
complement component
compound
Prior art date
Application number
CL2022001173A
Other languages
English (en)
Inventor
Antoni Krasinski
Yibin Zeng
Penglie Zhang
Rebecca M Lui
Kwok Yau
Rajinder Singh
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CL2022001173A1 publication Critical patent/CL2022001173A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona una forma cristalina de la base libre de un receptor del componente del complemento 5a que tiene la fórmula del Compuesto 1. También se proporcionan composiciones farmacéuticas y métodos de tratamiento usando la forma cristalina de la base libre del Compuesto 1 descrita aquí.
CL2022001173A 2019-11-08 2022-05-04 Forma cristalina de la base libre de un receptor del componente c5a del complemento CL2022001173A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962932652P 2019-11-08 2019-11-08

Publications (1)

Publication Number Publication Date
CL2022001173A1 true CL2022001173A1 (es) 2023-02-10

Family

ID=75846182

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001173A CL2022001173A1 (es) 2019-11-08 2022-05-04 Forma cristalina de la base libre de un receptor del componente c5a del complemento

Country Status (13)

Country Link
US (3) US11026935B2 (es)
EP (1) EP4054577A4 (es)
JP (1) JP2022554019A (es)
KR (1) KR20220098179A (es)
CN (1) CN114641289A (es)
AU (1) AU2020378061A1 (es)
BR (1) BR112022007488A2 (es)
CA (1) CA3155596A1 (es)
CL (1) CL2022001173A1 (es)
IL (1) IL292317A (es)
MX (1) MX2022005403A (es)
WO (1) WO2021092292A1 (es)
ZA (1) ZA202305622B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005406A (es) 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CA3155950A1 (en) 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
WO2022093971A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260036B1 (ko) 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
PL2381778T3 (pl) 2008-12-22 2017-01-31 Chemocentryx, Inc. Antagoniści c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
WO2016053890A1 (en) 2014-09-29 2016-04-07 Chemocentryx, Inc. PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
CA3155950A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Also Published As

Publication number Publication date
US20210137907A1 (en) 2021-05-13
KR20220098179A (ko) 2022-07-11
US20220096453A1 (en) 2022-03-31
JP2022554019A (ja) 2022-12-27
CA3155596A1 (en) 2021-05-14
EP4054577A1 (en) 2022-09-14
MX2022005403A (es) 2022-05-24
US20230381167A1 (en) 2023-11-30
ZA202305622B (en) 2024-01-31
WO2021092292A1 (en) 2021-05-14
EP4054577A4 (en) 2023-11-29
US11026935B2 (en) 2021-06-08
IL292317A (en) 2022-06-01
BR112022007488A2 (pt) 2022-07-12
CN114641289A (zh) 2022-06-17
AU2020378061A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
CL2022001172A1 (es) Forma amorfa de un receptor del componente c5a del complemento
AR125321A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
PE20221339A1 (es) Inhibidores de parp1
CL2021001461A1 (es) Moduladores de trex1
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
MD3481846T2 (ro) 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
NI202100018A (es) Moduladores de la expresión de pnpla3
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
CY1121693T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2022001183A1 (es) Formas de sal de un receptor del componente c5a del complemento
AR119174A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
CO2023015732A2 (es) Moduladores de trex1
MX2020003554A (es) Moduladores de la expresion de enac.